期刊文献+

吉西他滨联合顺铂、艾迪治疗40例晚期肺腺癌的临床观察 被引量:2

下载PDF
导出
摘要 目的:观察应用吉西他滨联合顺铂、艾迪治疗晚期肺腺癌的疗效和不良反应,以及对生活质量的影响。方法:采用GP方案治疗晚期肺腺癌患者40例:吉西他滨1000mg/m2,第1、8天,静脉滴注,顺铂25mg/m2,第1~3天,静脉滴注,艾迪50ml,第1~8天,21d为1个周期,至少治疗2个周期。停药标准为:病情进展或出现不能耐受的不良反应。结果:一线治疗的患者31例,有30例可评价疗效,其中CR5例,PR13例,SD8例,PD4例,总有效率为60.0%(18/30),临床获益率为86.7%(26/30)。二线治疗的9例患者中:CR0例,PR4例,SD2例,PD3例,总有效率为44.4%(4/9),临床获益率为66.7%(6/9)。ECOG评分稳定及改善为62.5%(25/40)。最常见的不良反应为骨髓抑制,尤其是粒系抑制和血小板的抑制。结论:吉西他滨联合顺铂、艾迪治疗晚期肺腺癌疗效确切,能改善生活质量。应用过程中要注意严重的骨髓抑制问题,但值得在临床推广应用。
出处 《中国当代医药》 2011年第13期69-70,共2页 China Modern Medicine
  • 相关文献

参考文献7

二级参考文献47

  • 1王岩,徐建明,宋三泰.表皮生长因子受体靶向药物作用机制与相关标志物的研究现状[J].中华肿瘤杂志,2005,27(9):573-576. 被引量:33
  • 2杨鹭,刘叙仪,方健,安彤同,吴梅娜.吉非替尼治疗91例晚期非小细胞肺癌疗效分析[J].中华肿瘤杂志,2006,28(6):474-477. 被引量:36
  • 3Mok T, Wu YL, Thongprasert S, et al. Phase Ⅲ , randomised, open-label first-line study of Gefitinib (G) vs carboplatin/Paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small cell lung cancer (NSCLC) (IPASS)[J]. Annals of Oncology, 2008,19 (Suppl 8):LBA 2.
  • 4Sirera R, Catot S, Gonza'lez-Larriba JL, et al. Customizing Erlotinib in metastatic non-smallcell lung cancer (NSCLC) patients (p) harboring EGFR mutations [ J ]. Annals of Oncology, 2008,19 (Supplement 8) : 230 PD.
  • 5Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib [J]. N Engl J Med, 2004,350 : 2129-2139.
  • 6Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy [ J ]. Science, 2004,304 : 1497-1500.
  • 7Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and Gefitinib sensitivity in non-small-cell lung cancer [J]. J Natl Cancer Inst, 2005,97: 643-655.
  • 8Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer[J].J Clin Oncol, 2007,25 : 587-595.
  • 9Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with Gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in China's Mainland [J]. J Thorac Oncol, 2007,2:430-439.
  • 10Grigorescu AC,Draghici NH,Nitipur C,et al.Gemciabine and carboplation versus cisplatin and vinoreibine in advanced nan-small cell lung cancer stage ⅢA and Ⅳ:a Phase Ⅲ randomized trial[J].Lung Cancer,2002,37(5):9-11.

共引文献149

同被引文献16

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部